Johnson & Johnson JNJ
NYSE JNJ
$267.67 -5.77 (-2.11%)
At close: Aug 20, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Share-based Compensation (2009 - 2026)

Johnson & Johnson (JNJ) posted Share-based Compensation of $458.0 million for Q2 2026, up 52.67% sequentially from $300.0 million in Q1 2026, and up 11.71% YoY from $410.0 million in Q2 2025.

Johnson & Johnson (JNJ) Share-based Compensation (2009 - 2026) Analysis & Trends

Johnson & Johnson has reported Share-based Compensation for 18 years, with the latest figure at $458.0 million in Q2 2026.

  • Quarterly Share-based Compensation rose 11.71% year-over-year to $458.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 14.87% YoY) and the FY2025 annual result came in at $1.4 billion, up 15.14% from the prior year.
  • Share-based Compensation grew to $458.0 million in Q2 2026 per JNJ's latest filing, from $300.0 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $458.0 million in Q2 2026 and troughed at $178.0 million in Q4 2023.
  • A 5-year average of $309.1 million and a median of $301.0 million in 2024 frame the typical range for Share-based Compensation.
  • The sharpest annual moves came in 2023 and 2024: Share-based Compensation declined 18.35% in 2023, then jumped 33.71% in 2024.
  • Over 5 years, Share-based Compensation stood at $278.0 million in 2022, then slumped by 35.97% to $178.0 million in 2023, then soared by 33.71% to $238.0 million in 2024, then gained by 29.83% to $309.0 million in 2025, then surged by 48.22% to $458.0 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods registered $458.0 million, $300.0 million, and $309.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. (Qtr)
1 Johnson & Johnson 645.88 Bn 625.12 Bn 17.26 Bn 458.00 Mn
2 AbbVie 463.46 Bn 456.89 Bn 12.70 Bn 166.00 Mn
3 Merck 367.92 Bn 360.78 Bn 12.21 Bn 298.00 Mn
4 Novartis Ag 297.71 Bn 290.02 Bn 11.24 Bn -
5 Astrazeneca 255.55 Bn 250.65 Bn 12.86 Bn -
6 Amgen 234.52 Bn 220.53 Bn 7.24 Bn 165.00 Mn
7 Gilead Sciences 178.22 Bn 175.04 Bn 6.22 Bn 231.00 Mn
8 Pfizer 158.57 Bn 146.88 Bn 10.94 Bn 249.00 Mn
9 Gsk 105.32 Bn 101.15 Bn 8.24 Bn -
10 Sanofi 54.20 Bn 46.82 Bn 10.79 Bn -

Historic Data

Download Data
DateValue
Jun 28, 2026 458.00 Mn
Jun 28, 2026 458.00 Mn
Mar 29, 2026 300.00 Mn
Mar 29, 2026 300.00 Mn
Dec 28, 2025 309.00 Mn
Dec 28, 2025 309.00 Mn
Sep 28, 2025 347.00 Mn
Sep 28, 2025 347.00 Mn
Jun 29, 2025 410.00 Mn
Jun 29, 2025 410.00 Mn
Mar 30, 2025 288.00 Mn
Mar 30, 2025 288.00 Mn
Dec 29, 2024 238.00 Mn
Dec 29, 2024 238.00 Mn
Sep 29, 2024 295.00 Mn
Sep 29, 2024 295.00 Mn
Jun 30, 2024 341.00 Mn
Jun 30, 2024 341.00 Mn
Mar 31, 2024 302.00 Mn
Mar 31, 2024 302.00 Mn